Bristol-Myers Squibb Company Watch

EX-4.1

from 8-K 134 pages Bristol-Myers Squibb Company and the Bank of New York Mellon, as Trustee Fifteenth Supplemental Indenture Dated as of February 22, 2024 to Indenture Dated as of June 1, 1993

12/34/56

EX-4.1

from 8-K 64 pages Bristol-Myers Squibb Company and the Bank of New York Mellon, as Trustee Fourteenth Supplemental Indenture Dated as of November 13, 2023 to Indenture Dated as of June 1, 1993 $1,000,000,000 5.750% Notes Due 2031 $1,000,000,000 5.900% Notes Due 2033 $1,250,000,000 6.250% Notes Due 2053 $1,250,000,000 6.400% Notes Due 2063

12/34/56

EX-4.A

from 10-K 24 pages Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

12/34/56

EX-4.1

from 8-K 62 pages Bristol-Myers Squibb Company and the Bank of New York Mellon, as Trustee Thirteenth Supplemental Indenture Dated as of March 2, 2022 to Indenture Dated as of June 1, 1993 $1,750,000,000 2.950% Notes Due 2032 $1,250,000,000 3.550% Notes Due 2042 $2,000,000,000 3.700% Notes Due 2052 $1,000,000,000 3.900% Notes Due 2062

12/34/56

EX-4.A

from 10-K 35 pages Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

12/34/56

EX-4.A

from 10-K 28 pages Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

12/34/56

EX-4.1

from 8-K 87 pages Brhc10016928 Bristol-Myers Squibb Company and the Bank of New York Mellon, Trustee Twelfth Supplemental Indenture Dated as of November 13, 2020 to Indenture Dated as of June 1, 1993 $1,500,000,000 0.537% Notes Due 2023 $1,000,000,000 0.750% Notes Due 2025 $1,000,000,000 1.125% Notes Due 2027 $1,250,000,000 1.450% Notes Due 2030 $750,000,000 2.350% Notes Due 2040 $1,500,000,000 2.550% Notes Due 2050

12/34/56

EX-4.GGG

from 10-K 33 pages Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

12/34/56

EX-4.CCC

from 10-K 59 pages Contingent Value Rights Agreement by and Between Bristol-Myers Squibb Company and Equiniti Trust Company Dated as of November 20, 2019

12/34/56

EX-4.21

from 8-K 21 pages Registration Rights Agreement

12/34/56

EX-4.1

from 8-K 312 pages Bristol-Myers Squibb Company and the Bank of New York Mellon, Trustee Eleventh Supplemental Indenture Dated as of November 22, 2019 to Indenture Dated as of June 1, 1993

12/34/56

EX-4.2

from 8-K 6 pages Assignment, Assumption and Amendment Agreement

12/34/56

EX-4.1

from 8-K 59 pages Contingent Value Rights Agreement by and Between Bristol-Myers Squibb Company and Equiniti Trust Company Dated as of November 20, 2019

12/34/56

EX-4.1

from 8-A12B 59 pages Contingent Value Rights Agreement by and Between Bristol-Myers Squibb Company and Equiniti Trust Company Dated as of [ ], [ ]

12/34/56

EX-4.11

from 8-K 24 pages Registration Rights Agreement

12/34/56

EX-4.1

from 8-K 188 pages Bristol-Myers Squibb Company and the Bank of New York Mellon, Trustee Tenth Supplemental Indenture Dated as of May 16, 2019 to Indenture Dated as of June 1, 1993

12/34/56

EX-4.1

from 8-K 22 pages Bristol-Myers Squibb Company and the Bank of New York Mellon, Trustee Ninth Supplemental Indenture Dated as of February 27, 2017 to Indenture Dated as of June 1, 1993 1.600% Notes Due 2019 3.250% Notes Due 2027

12/34/56

EX-4.3

from 8-K 11 pages Bristol-Myers Squibb Company 1.750% Notes Due 2035

12/34/56

EX-4.2

from 8-K 11 pages Bristol-Myers Squibb Company 1.000% Notes Due 2025

12/34/56

EX-4.1

from 8-K 35 pages Bristol-Myers Squibb Company and the Bank of New York Mellon, Trustee Eighth Supplemental Indenture Dated as of May 5, 2015 to Indenture Dated as of June 1, 1993 1.000% Notes Due 2025 1.750% Notes Due 2035

12/34/56